IGC Pharma (IGC) Tax Provisions (2010 - 2024)

IGC Pharma (IGC) has reported Tax Provisions for 14 consecutive years, with -$2.7 million the latest figure, recorded in Q1 2024.

• On a quarterly basis, Tax Provisions fell 13.0% year-over-year to -$2.7 million in Q1 2024; TTM through Dec 2024 was -$2.7 million, a 13.0% decrease from a year earlier, with the FY2025 full-year figure at -$2.3 million, up 15.57% from the prior year.
• Tax Provisions was -$2.7 million for Q1 2024 at IGC Pharma, down from -$2.4 million in the prior quarter.
• Over five years, Tax Provisions peaked at -$1.8 million in Q1 2021 and troughed at -$3.2 million in Q1 2022.
• A 5-year average of -$2.6 million and a median of -$2.7 million in 2024 frame the typical range for Tax Provisions.
• Across the five-year window, Tax Provisions tumbled 458.72% in 2020 and soared 40.03% in 2021, its largest moves.
• Over 5 years, Tax Provisions stood at -$3.1 million in 2020, then soared by 40.03% to -$1.8 million in 2021, then plunged by 70.43% to -$3.2 million in 2022, then climbed by 23.37% to -$2.4 million in 2023, then retreated by 13.0% to -$2.7 million in 2024.
• The last three Tax Provisions figures came in at -$2.7 million (Q1 2024), -$2.4 million (Q1 2023), and -$3.2 million (Q1 2022), per Business Quant data.